Attenuated mannheimia haemolytica strains
AssigneesThe United States of America as represented by the Secretary of Agriculture, Biotechnology Research and Development Corporation
InventorsRobert E. Briggs, Fred M. Tatum
Life of this patent
Estimating the term…
Abstract
The present invention provides attenuated M haemolitica strains that elicit an immune response in animal against M haemolitica, compositions comprising said strains, methods of vaccination against M haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease.
Claims9
1-48. (canceled)
A kit comprising a first container comprising an attenuated M. haemolytica and instructions on administering said attenuated M. haemolytica to an animal, wherein said attenuated M. haemolytica comprises a deletion within the LktCA gene locus encoding acylase (LktC) and leukotoxin A (LktA);
- and wherein said attenuated M. haemolytica bacterium secretes a truncated LktCA having an amino acid sequence set forth in SEQ ID NO:
- 18.
A kit comprising (i) a first container comprising an attenuated M. haemolytica serotype A1 D153 comprising a mutated LktCA gene locus that encodes a truncated LktCA having an amino acid sequence set forth in SEQ ID NO:
- 18, (ii) a second container comprising an attenuated M. haemolytica serotype A6 D174 comprising a mutated LktCA gene locus that encodes a truncated LktCA having an amino acid sequence set forth in SEQ ID NO:
- 18, and (iii) instructions on administering said attenuated M. haemolytica to an animal.
Dependencies are inferred from the claim text.